obesity

News

AbbVie pays Gubra $350m upfront to enter obesity field

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.

News

Lilly launches discounted high-strength Zepbound vials in US

Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.

News

Compounders cast adrift after semaglutide shortage ends

The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.

Digital

Looking beyond the scale: Why measures of physical activity ...

GLP-1 receptor agonists like Ozempic and Wegovy are dramatically changing how healthcare professionals approach the treatment of obesity in patients.

R&D

Will 2025 be the year the pharmaceutical industry finds its ...

After spending 2024 in recovery mode, the biopharma industry is finally showing signs of growth, climbing back toward its pre-pandemic heights.

News

Pharma group slams Hims & Hers over Super Bowl GLP-1 ad

Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."

AbbVie pays Gubra $350m upfront to enter obesity field

Lilly launches discounted high-strength Zepbound vials in US

Compounders cast adrift after semaglutide shortage ends

Looking beyond the scale: Why measures of physical activity ...

Will 2025 be the year the pharmaceutical industry finds its ...

Pharma group slams Hims & Hers over Super Bowl GLP-1 ad

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

obesity

Editor's Picks